The natural product industry is booming and showing no signs of slowing. Big brands are taking note by scooping up smaller, innovative companies that are disrupting consumer products by adding a natural twist. Michael Cammarata, Co-Founder and CEO of Schmidt's Naturals, shared why his company was such an attractive target for Unilever.
Cammarata said Unilever was drawn to his brand due to its rapid growth and ability to go to market quickly. He said consumers have been the brands biggest advocate. The entrepreneur also added that the Unilever focuses on the founders and allows them to continue to operate the way they want.
All-natural has been all the rage as consumers increasingly opt for chemical-free products. He says his brand is unique because they focused on competing with brands in the traditional space. He added consumers are realizing products with natural ingredients are delivering similar results as the initial products.
The Week's Top Stories is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Federal Reserve Chair Jerome Powell was tricked into an extended phone call in January with Russian pranksters posing as Ukrainian President Volodymyr Zelenskyy, during which Powell appeared to discuss the economic impact of interest rate hikes.
Amazon on Thursday reported stronger-than-expected revenue and profits for the first quarter, sending its stocks higher in after-hours trading. But its prices took a dip in the evening amid concerns about a continued slowdown in the company's profitable cloud computing unit AWS.
A key index of underlying inflation that is closely followed by the Federal Reserve remained elevated last month, keeping the Fed on track to raise interest rates next week for the 10th time since March of last year.
As a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
